Mosam A, Uldrick TS, Shaik F, Carrara H, Aboobaker J, Coovadia H. An evaluation of the early effects of a combination antiretroviral therapy programme on the management of AIDS-associated Kaposi’s sarcoma in KwaZulu-Natal, South Africa. Int J STD AIDS 2011; 22(11): 671-3.
Ngalamika O, Minhas V, Wood C. Kaposi’s sarcoma at the University Teaching Hospital, Lusaka, Zambia in the antiretroviral therapy era. Int J Cancer 2015; 136(5): 1241-2.
Robey RC, Bower M. Facing up to the ongoing challenge of Kaposi’s sarcoma. Curr Opin Infect Dis 2015; 28(1): 31-40.
Makombe SD, Harries AD, Yu JK, et al. Outcomes of patients with Kaposi’s sarcoma who start antiretroviral therapy under routine programme conditions in Malawi. Trop Doct 2008; 38(1): 5-7.
GLOBOCAN, Estimated Cancer Incidence, Mortality and Prevalence Worldwide. WHO 2012.
Engels EA, Pfeiffer RM, Goedert JJ, et al. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS 2006; 20(12): 1645-54.
Mosam A, Aboobaker J, Shaik F. Kaposi’s sarcoma in sub-Saharan Africa: a current perspective. Curr Opin Infect Dis 2010; 23(2): 119-23.
Schwartz RA, Micali G, Nasca MR, Scuderi L. Kaposi sarcoma: a continuing conundrum. J Am Acad Dermatol 2008; 59(2): 179- 206; 7-8.
Krown SE. Treatment strategies for Kaposi sarcoma in sub-Saharan Africa: challenges and opportunities. Curr Opin Oncol 2011; 23(5): 463-8.
Northfelt DW, Dezube BJ, Thommes JA, et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi’s sarcoma: results of a randomized phase III clinical trial. J Clin Oncol 1998; 16(7): 2445-51.
Gbabe OF, Okwundu CI, Dedicoat M, Freeman EE. Treatment of severe or progressive Kaposi’s sarcoma in HIV-infected adults. Cochrane Database Syst Rev 2014; (8): CD003256.
Nunez M, Saballs P, Valencia ME, et al. Response to liposomal doxorubicin and clinical outcome of HIV-1-infected patients with Kaposi’s sarcoma receiving highly active antiretroviral therapy. HIV Clin Trials 2001; 2(5): 429-37.
Mosam A, Shaik F, Uldrick TS, et al. A randomized controlled trial of highly active antiretroviral therapy versus highly active antiretroviral therapy and chemotherapy in therapy-naive patients with HIV-associated Kaposi sarcoma in South Africa. J Acquir Immune Defic Syndr 2012; 60(2): 150-7.
Nguyen HQ, Magaret AS, Kitahata MM, Van Rompaey SE, Wald A, Casper C. Persistent Kaposi sarcoma in the era of highly active antiretroviral therapy: characterizing the predictors of clinical response. AIDS 2008; 22(8): 937-45.
Steegmann JL, Sanchez Torres JM, Colomer R, et al. Prevalence and management of anaemia in patients with non-myeloid cancer undergoing systemic therapy: a Spanish survey. Clin Transl Oncol 2013; 15(6): 477-83.
Gwaram BA, Yusuf SM. Clinical presentation and treatment outcome of HIV associated Kaposi sarcoma in a tertiary health centre in Nigeria. J Med Res 2016; 2(4): 110-3.